Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Kurt Schmidt, Henk Viëtor

Premium

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009. Before Agendia, Schmidt was operations director at B2eMarkets and he was director of finance and operations at LA Gear Europe. In connection with Schmidt's appointment, Skyline's former CEO Henk Viëtor has been appointed to the supervisory board of the Rotterdam, Netherlands-based company.

In a statement, Skyline noted that Agendia is "not dissimilar" to itself, as it has also commercialized microarray-based tests for cancer. The firm also said that it is "entering a new phase" with Schmidt's appointment. Skyline achieved a CE-IVD mark for its AMLprofiler test in 2011 and is conducting clinical trials for an eventual US Food and Drug Administration submission (BAN 3/15/2011).

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.